A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Abexinostat (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms RENAVIV
- Sponsors Xynomic Pharmaceuticals
- 27 Dec 2018 According to a media release, the company will discuss Trials-in-Progress poster of this study at the ASCO-Genitourinary Cancers Symposium (Feb 2019).
- 06 Aug 2018 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 New trial record